These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 25151742)

  • 41. Experimental design and efficient parameter estimation in preclinical pharmacokinetic studies.
    Ette EI; Howie CA; Kelman AW; Whiting B
    Pharm Res; 1995 May; 12(5):729-37. PubMed ID: 7479560
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Interpretation of simulation studies for efficient estimation of population pharmacokinetic parameters.
    Ette EI; Kelman AW; Howie CA; Whiting B
    Ann Pharmacother; 1993 Sep; 27(9):1034-9. PubMed ID: 8117353
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacokinetic models to assist the prescriber in choosing the best tacrolimus dose.
    Woillard JB; Saint-Marcoux F; Debord J; Åsberg A
    Pharmacol Res; 2018 Apr; 130():316-321. PubMed ID: 29452291
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Accelerating Monte Carlo power studies through parametric power estimation.
    Ueckert S; Karlsson MO; Hooker AC
    J Pharmacokinet Pharmacodyn; 2016 Apr; 43(2):223-34. PubMed ID: 26934878
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Performance of an iterative two-stage bayesian technique for population pharmacokinetic analysis of rich data sets.
    Proost JH; Eleveld DJ
    Pharm Res; 2006 Dec; 23(12):2748-59. PubMed ID: 17089202
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Estimation of drug exposure by machine learning based on simulations from published pharmacokinetic models: The example of tacrolimus.
    Woillard JB; Labriffe M; Prémaud A; Marquet P
    Pharmacol Res; 2021 May; 167():105578. PubMed ID: 33775863
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evaluation of FOCEI and SAEM Estimation Methods in Population Pharmacokinetic Analysis Using NONMEM
    Sukarnjanaset W; Wattanavijitkul T; Jarurattanasirikul S
    Eur J Drug Metab Pharmacokinet; 2018 Dec; 43(6):729-736. PubMed ID: 29785609
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Identification of the glucose minimal model by stochastic nonlinear-mixed effects methods.
    Largajolli A; Bertoldo A; Cobelli C
    Annu Int Conf IEEE Eng Med Biol Soc; 2012; 2012():5482-5. PubMed ID: 23367170
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Shrinkage in nonlinear mixed-effects population models: quantification, influencing factors, and impact.
    Xu XS; Yuan M; Karlsson MO; Dunne A; Nandy P; Vermeulen A
    AAPS J; 2012 Dec; 14(4):927-36. PubMed ID: 22993107
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Population pharmacokinetics of higher-dose mizoribine in healthy male volunteers.
    Honda M; Itoh H; Suzuki T; Hashimoto Y
    Biol Pharm Bull; 2006 Dec; 29(12):2460-4. PubMed ID: 17142982
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Application of Fourier amplitude sensitivity test in Chinese healthy volunteer population pharmacokinetic model of tacrolimus].
    Guan Z; Zhang GM; Ma P; Liu LH; Zhou TY; Lu W
    Yao Xue Xue Bao; 2010 Jul; 45(7):883-90. PubMed ID: 20931787
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Experimental design and efficient parameter estimation in population pharmacokinetics.
    al-Banna MK; Kelman AW; Whiting B
    J Pharmacokinet Biopharm; 1990 Aug; 18(4):347-60. PubMed ID: 2231324
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparison of ED, EID, and API criteria for the robust optimization of sampling times in pharmacokinetics.
    Tod M; Rocchisani JM
    J Pharmacokinet Biopharm; 1997 Aug; 25(4):515-37. PubMed ID: 9561492
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Simulation for clinical repeated-dose pharmacokinetic trials applying a peak-and-trough sampling design to estimate oral clearance.
    Ishida K; Kayano Y; Taguchi M; Hashimoto Y
    Biol Pharm Bull; 2007 Nov; 30(11):2159-62. PubMed ID: 17978492
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Can We Predict Individual Concentrations of Tacrolimus After Liver Transplantation? Application and Tweaking of a Published Population Pharmacokinetic Model in Clinical Practice.
    Decrocq-Rudler MA; Chan Kwong AHP; Meunier L; Fraisse J; Ursic-Bedoya J; Khier S
    Ther Drug Monit; 2021 Aug; 43(4):490-498. PubMed ID: 33560099
    [TBL] [Abstract][Full Text] [Related]  

  • 56. On the recording of sample times and parameter estimation from repeated measures pharmacokinetic data.
    Sun H; Ette EI; Ludden TM
    J Pharmacokinet Biopharm; 1996 Dec; 24(6):637-50. PubMed ID: 9300354
    [TBL] [Abstract][Full Text] [Related]  

  • 57. PFIM 4.0, an extended R program for design evaluation and optimization in nonlinear mixed-effect models.
    Dumont C; Lestini G; Le Nagard H; Mentré F; Comets E; Nguyen TT;
    Comput Methods Programs Biomed; 2018 Mar; 156():217-229. PubMed ID: 29428073
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Development of limited sampling strategies for characteristics of a pharmacokinetic profile.
    Sallas WM
    J Pharmacokinet Biopharm; 1995 Oct; 23(5):515-29. PubMed ID: 8656345
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Predicting model-informed precision dosing: A test-case in tacrolimus dose adaptation for kidney transplant recipients.
    Faelens R; Luyckx N; Kuypers D; Bouillon T; Annaert P
    CPT Pharmacometrics Syst Pharmacol; 2022 Mar; 11(3):348-361. PubMed ID: 35020971
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Extension of the SAEM algorithm for nonlinear mixed models with 2 levels of random effects.
    Panhard X; Samson A
    Biostatistics; 2009 Jan; 10(1):121-35. PubMed ID: 18583352
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.